<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00682747</url>
  </required_header>
  <id_info>
    <org_study_id>KKSH-037</org_study_id>
    <nct_id>NCT00682747</nct_id>
  </id_info>
  <brief_title>Hyperbaric Oxygen for the Treatment of a Dry Mouth Which Occurred After Radiotherapy</brief_title>
  <official_title>Randomized Phase II Trial of Hyperbaric Oxygen for the Treatment of Radiation-induced Xerostomia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Kuhnt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Verband Deutscher Druckkammerzentren</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Martin-Luther-Universität Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether hyperbaric oxygen is effective in the
      treatment of a dry mouth that occured after radiotherapy for head and neck tumours.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor recruitment
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of overall salivation (millilitre per minute over 5 minutes measured at rest and after provocation) in percentages</measure>
    <time_frame>baseline compared with measures on day 28, 56 and 146</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events in all patients as a Measure of Safety and Tolerability</measure>
    <time_frame>baseline until 4 weeks after end of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Xerostomia scores assessed by investigator according to Eisbruch et.al.</measure>
    <time_frame>baseline compared with measures on day 28, 56 and 146</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of symptoms/discomfort due to xerestomia assessed by the patient on a visual analogue scale</measure>
    <time_frame>baseline compared with measures on day 28, 56 and 146</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life measures (EORTC QLQ-H&amp;N 35)</measure>
    <time_frame>baseline compared with measures on day 28, 56 and 146</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Radiation-induced Xerostomia</condition>
  <arm_group>
    <arm_group_label>HBO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 treatments with hyperbaric oxygen once per day, five days per week, 2.4 ATA, 100 % oxygen (10-15 minutes compression with air, 90 min of oxygen breathing - two 10 minutes break for breathing air after each 30 minutes of oxygen, 10 minutes decompression with oxygen)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non HBO</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric oxygen</intervention_name>
    <description>40 treatments with hyperbaric oxygen once per day, five days per week, 2.4 ATA, 100 % oxygen (10-15 minutes compression with air, 90 min of oxygen breathing - two 10 minutes break for breathing air after each 30 minutes of oxygen, 10 minutes decompression with oxygen</description>
    <arm_group_label>HBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  complaints of xerostomia (visual analogue scale)

          -  at least 6 months after radiotherapy of the head and neck region including all
             salivary glands with at least 50 Gy

          -  objective hyposalivation / xerostomia (at rest &lt; 0,25 ml saliva per minute, stimulated
             &lt; 0,1 ml saliva per minute)

          -  patient must have given written informed consent

        Exclusion Criteria:

          -  prior radiotherapy was an intensity modulated radiotherapy

          -  prior hyperbaric oxygen therapy after radiotherapy

          -  conditions which might be an additional risk for the treatment with hyperbaric oxygen
             such as spontaneous pneumothorax within the last two years, surgery of the eardrum or
             the middle ear, acute infection of the upper airways, not adequately treated epilepsy,
             concurrent radio- or chemotherapy, hereditary spherocytosis, psychosis, lung
             emphysema, asthma, severe COPD, prior surgery of the thorax, pace maker

          -  myocardial infarction within the last 6 months

          -  drug therapy which might induce xerostomia

          -  known intolerance or hypersensitivity to Wrigley's Freident®

          -  pregnancy or breast-feeding women (for women aged less than 60 years a pregnancy test
             is mandatory)

          -  women of childbearing potential with unclear contraception. The following
             contraceptive methods are recommended: combined oral contraceptives or
             progesterone-only pill, hormone-dispensing or copper intra-uterine system, hormone
             patches, long-acting injections, vaginal ring

          -  treatment with other investigational drugs or participation in another clinical trial
             within 30 days prior to enrollment

          -  refusal of cooperation or consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Kuhnt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Rostock, Clinic for Radiotherapy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Martin Luther University Halle-Wittenberg, Clinic for Radiotherapy</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Druckkammerzentrum Traunstein</name>
      <address>
        <city>Traunstein</city>
        <zip>83278</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2008</study_first_submitted>
  <study_first_submitted_qc>May 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2008</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Martin-Luther-Universität Halle-Wittenberg</investigator_affiliation>
    <investigator_full_name>Thomas Kuhnt</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>xerostomia</keyword>
  <keyword>hyperbaric oxygenation</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Xerostomia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

